Board of Directors
Dr. James C. Walker
Dr. James (Jim) Walker is the Executive Chairman of Zoomi, Inc. Prior to his role at Zoomi, Jim was a Partner at Accenture, LLP where he led the growth and strategy for a life sciences unit selling software and services. Additionally, Jim co-founded and served as the Chief Executive Officer of Octagon Research Solutions, which was acquired by Accenture, LLP in 2012.
Jim is the recipient of the Ernst & Young Entrepreneur of the Year Award, the ‘Stevie Award’ for Most Innovative Company at the American Business Awards, and the Greater Philadelphia Alliance for Capital and Technologies (PACT) Enterprise Awards Technology CEO of the Year. Jim is a graduate of Villanova University earning a B.S. in Science Comprehensive. Jim also earned an M.S. in Environmental Science from Rutgers University, an M.B.A. from Duke University and his Doctorate degree from the University of Pennsylvania. His dissertation was an exploratory study on adaptability in the workplace.
Dr. Neal Walker
Dr. Neal Walker is the President and Chief Executive Officer of Aclaris. He is a board certified dermatologist and serial entrepreneur with more than 18 years of experience in the biopharmaceutical industry.
Prior to founding Aclaris, he was co-founder, President and CEO of Vicept Therapeutics (acquired by Allergan). Neal has co-founded and led a number of life science companies: Octagon Research Solutions, a software and services provider to biopharmaceutical companies (acquired by Accenture); Trigenesis Therapeutics, a specialty dermatology company where he served as Chief Medical Officer (acquired by Dr. Reddy’s Laboratories); and Cutix Inc., a commercial dermatology company that markets PreSun®, a sunscreen brand acquired from Bristol-Myers Squibb.
He began his pharmaceutical industry career at Johnson and Johnson. Neal currently is on the Board of Directors of Sebacia, Inc. and Follica, Inc. (Executive Chairman), and is on the Advisory Board of Flexible Medical Systems. He previously served on the Board of Directors for Octagon. Neal received his M.B.A. from University of Pennsylvania’s Wharton School.
Dr. Mung Chiang
Dr. Mung Chiang is the Arthur LeGrand Doty Professor of Electrical Engineering at Princeton University. He is also the Director of Keller Center for Innovation in Engineering Education and Chairman of Princeton Entrepreneurship Advisory Committee, for which he was named a New Jersey Non-Profit CEO of the Year (2014). His research on networking received the Alan T. Waterman Award (2013), the highest award to young scientists in the U.S., the IEEE Kiyo Tomiyasu Award (2012), a Guggenheim Fellowship (2014), and many other research and publication awards. A Technology Review TR35 Young Innovator Award recipient (2007) and founder of the Princeton EDGE Lab, his technologies have resulted in several commercial adoptions.
His education activities received the Frederick Emmons Terman Award (2013) from American Society of Engineering Education. His MOOC reached 200,000 students in 2012-2014. The corresponding textbook, “Networked Life: 20 Questions and Answers” received the PROSE Award in Engineering and Technology (2012) from the Association of American Publishers. He has been an invited speaker at numerous venues of learning technology and policy conferences, and is one of the national experts contributing to the Presidential Council of Advisors in Science and Technology’s report on Education Information Technology.
Steve Tullman is the Managing Partner of NeXeption, a biopharmaceutical management company that brings together product opportunities, management expertise and the necessary funding to build biopharmaceutical companies focused on reaching compelling partnership milestones. He brings more than 25 years of biopharmaceutical global commercialization and drug development experience. Within the NeXeption portfolio companies, Steve is currently the Chairman of Aclaris Therapeutics, Chairman of Alexar Therapeutics and a founding partner of Celaris Therapeutics. He recently served as the CEO and Chairman of Ceptaris Therapeutics, acquired by Actelion in 2013.
Previously, Steve was Chairman of Vicept Therapeutics, acquired by Allergan in 2011. He was the Chief Executive Officer of Ception Therapeutics, acquired by Cephalon in 2010. He was also the Chief Business Officer and co-founder of Trigenesis, acquired by Dr. Reddy’s Laboratories in 2004. He started his career at SmithKline Beecham.
Ray Solomon is an investor advisor for successful start-ups across multiple industries. He has been practicing law independently in the New York City area since 1979, specializing in litigation and business law. In addition to his law practice, he has led several successful startup transactions, beginning with Brunson Communications (a Philadelphia based independent television station) where he acted as lead shareholder until their sale in 1996 to Trinity Broadcasting for $48M. Additionally, Ray is co-founder of the James Hotel Brand, which he developed, operated and led to successful exit in 2006. He also has a history of successful investments across several biotech ventures.
Ray received his Bachelor of Science degree from the School of Industrial and Labor Relations, Cornell University in 1975 and his Juris Doctor (cum laude) from Syracuse University in 1978.
Mr. Goodwin is currently a private investor. Most recently from 2012-2018, he was the co-founder and Portfolio Manager of Panning Capital Management, a hedge fund with $2.5 billion AUM at its peak. Prior to Panning, he spent six years at King Street Capital Management. where he was named Partner and Head of Trading. From 2002 to 2004, Mr. Goodwin was Managing Director in UBS Principal Finance, where he ran his own prop trading book. Before UBS, he was a Managing Director in Fixed Income at Merrill Lynch and from 1991 until 1997 he was a trader in interest rate and credit derivatives at Smith Barney, Citigroup and Salomon Brothers. Mr. Goodwin is a graduate, cum laude, of Duke University (1991) with a BA in Computer Science.